Enlivex Therapeutics is set to conduct a reverse merger with publicly traded Bioblast Pharma, which will be renamed to Enlivex following the transaction.
Enilvex Therapeutics, an Israel-based immunotherapy developer backed by medical provider Hadassah University Hospital, is set to undertake a reverse merger of biotechnology firm Bioblast Pharma.
Upon closure of the transaction, Bioblast will rename to Enilvex Therapeutics and its ticker symbol on Nasdaq will be adapted from the current ORPN. The deal is expected to close in the first quarter of 2019.
Enlivex Therapeutics is working on immunotherapies for life-threatening immune and inflammatory conditions with an unmet medical need, such as…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
